Thurston Springer Miller Herd & Titak Inc. Decreases Holdings in Zoetis Inc. $ZTS

Thurston Springer Miller Herd & Titak Inc. decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 94.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 826 shares of the company’s stock after selling 13,153 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in Zoetis were worth $121,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. Vanguard Group Inc. boosted its position in Zoetis by 0.8% during the second quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock valued at $6,532,276,000 after buying an additional 330,823 shares during the period. Geode Capital Management LLC lifted its stake in shares of Zoetis by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after acquiring an additional 95,294 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Zoetis by 1.2% in the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after acquiring an additional 78,508 shares during the last quarter. Norges Bank purchased a new stake in Zoetis during the 2nd quarter valued at about $809,491,000. Finally, Brown Advisory Inc. grew its position in Zoetis by 5.7% during the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after acquiring an additional 250,829 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ZTS shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Morgan Stanley decreased their target price on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research note on Monday, November 10th. Barclays assumed coverage on shares of Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target for the company. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday. Finally, BTIG Research reaffirmed a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research note on Wednesday, December 3rd. Six equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, Zoetis presently has an average rating of “Hold” and an average target price of $161.55.

Zoetis Stock Up 2.0%

Shares of NYSE ZTS opened at $123.36 on Wednesday. The firm has a fifty day simple moving average of $130.07 and a two-hundred day simple moving average of $145.30. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.40. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $54.36 billion, a PE ratio of 20.77, a price-to-earnings-growth ratio of 2.51 and a beta of 0.97.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the previous year, the firm posted $1.58 EPS. The company’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be issued a dividend of $0.53 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.